Plasma monocyte chemoattractant protein-1 as risk marker in type 2 diabetes mellitus and coronary artery disease in North Indians

Abstract

The chemokine monocyte chemoattractant protein-1 (MCP-1) is implicated in chronic inflammation, insulin resistance and atherosclerosis. The present study was designed to explore the relation of plasma levels of MCP-1 to disease pathology in type 2 diabetes and coronary artery disease (CAD) patients. Fasting plasma venous samples were taken from 162 subjects divided into four groups: Patients with type 2 diabetes mellitus and CAD (n=41), type 2 diabetes patients without CAD (n=50), CAD patients with no history of diabetes (n=41) and healthy controls (n=30). Coronary risk factors such as body mass index, percentage body fat, waist/hip ratio, blood pressure and physical activity were measured using standard procedures. Plasma MCP-1 was quantitatively estimated by sandwich enzyme-linked immunoabsorbent assay (ELISA). Significant differences were observed for MCP-1 levels, percent body fat, body mass index, waist/hip ratio, systolic and diastolic blood pressure amongst the groups. MCP-1 concentration was significantly correlated with diabetes duration (p<0.001), body mass index (p<0.01), waist/hip ratio (p<0.01), systolic blood pressure (p<0.01), percentage body fat (p<0.01) and physical activity level (p<0.001). MCP-1 might serve as a marker for CAD, and its association with CAD is mainly driven by traditional coronary risk factors.

Keywords

monocyte chemoattractant protein-1 (MCP-1)diabetes coronary artery disease North Indians

References

Ford ES ( 1999) Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 22:1971-7.

Ross R. ( 1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-26.

Gokulakrishnan K. , Deepa R. , Mohan V. (2008) Association of high sensitivity C-Reactive Protein [hsCRP] and tumour necrosis factor-α [TNF-α] with carotid intimal medial thickness in subjects with different grades of glucose intolerance-The Chennai Urban Rural Epidemiology Study (CURES-31). Clin Biochem 41:480-5.

Piemonti L. , Colori G. , Mercalli A. et al. (2003) Fasting plasma leptin, tumor necrosis factor-α receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 26:2883-9.

Martinovic I. , Abegunewardene N. , Seul M. et al. (2005) Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 69:1484-9.

Herder C. , Muller-Scholze S. , Rating P. et al. (2006) Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Eur J Endocrinol 154:311-17.

Stehouwer CDA , Gall MA , Twisk JWR et al. (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157-65.

McDermott DH , Yang Q. , Kathiresan S. et al. (2005) CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112: 1113-20.

Catalan V. , Gomez-Ambrosi J. , Ramirez B. et al. (2008) Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 17: 1464-74.

10.

Rothenbacher D. , Hoffmeister A. , Brenner H. et al. (2003) Physical activity, coronary heart disease and inflammatory response. Arch Intern Med 163: 1200-5.